Hansa Medical AB (publ) today announced that the first patient has been treated
and subsequently transplanted in the pivotal multicenter study Highdes using
IdeS to desensitize highly sensitized patients prior to kidney transplantation.
The Phase II study will include approximately 20 highly sensitized patients
awaiting kidney transplantation. Patients included in this new study have either
failed on previous attempts of desensitization or the currently available
methods are considered insufficiently effective.
The study is entitled “A Phase II Study to Evaluate the Efficacy of IdeS (IgG
endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch
Test” with the short name Highdes. The primary objective of the study is to
assess the efficacy of IdeS in creating a negative crossmatch test in highly
sensitized patients with a positive crossmatch test to their available donor.
Converting the crossmatch test will enable transplantation in patients who would
otherwise not qualify for transplantation.
The study will also evaluate safety, kidney function and immunogenicity during
the 6-month follow-up period. The aim is to complete recruitment of
approximately 20 patients over a 12-month period.
"We are very pleased that the first patient has been treated in our Hansa
Medical-sponsored study with IdeS in the US. The study will recruit patients
with an urgent need for kidney transplantation. Several of the patients have
been on the waiting list for many years”, commented Göran Arvidson, President
and CEO of Hansa Medical AB.
It is expected that the study will provide pivotal data for filing a Biologics
License Application, i.e. an application to the US Food and Drug Administration
(FDA) for authorization to commercialize IdeS in the US. Three US sites will
recruit patients to the Highdes study: Cedars-Sinai Medical Center in Los
Angeles, The Johns Hopkins Hospital in Baltimore and New York University School
of Medicine in New York. Hansa Medical is planning to add European sites to the
study in order to support the regulatory process at the European Medicines
Agency, EMA, for marketing authorization of IdeS in the European market.
More information about this study in refractory highly sensitized patients is
available at www.clinicaltrials.gov under the identifier NCT02790437.
The information in this press release is disclosed pursuant to the EU Market
Abuse Regulation. The information was released for public disclosure through the
agency of the contact person stated below on October 3, 2016 at 08.30 CET.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations,
Hansa Medical AB (publ)
Göran Arvidson, CEO
, Hansa Medical AB (publ)
Mobile: +4670633 3042
About highly sensitized patients
Approximately one third of the kidney patients in dialysis are sensitized to
human leukocyte antigens (HLA). The presence of antibodies that react with a
potential donor organ and create a positive crossmatch test is a significant
barrier to transplantation due to the risk of acute antibody mediated rejection.
Sensitized patients in general have an increased waiting time for
transplantation. Depending on the level of HLA-immunization, some sensitized
patients can be transplanted with treatment procedures using for example
plasmapheresis or intravenous gamma globulin at specialized clinics. Patients
included in the Highdes study will have failed on previous attempts of
desensitization or will not be eligible for desensitization using currently
available methods due to the strength and breadth of their HLA antibodies. These
patients have one of the highest unmet medical needs in transplantation today.
IdeS, a unique molecule with a novel mechanism, is an enzyme that specifically
cleaves human IgG antibodies. IdeS has been evaluated in a Phase I study in
healthy subjects and in a Phase II study in sensitized patients awaiting kidney
transplantation demonstrating that IdeS is highly effective in reducing anti-HLA
antibodies to levels acceptable for transplantation with a favorable safety
profile. In addition to the pivotal Highdes study, the efficacy and safety of
IdeS in transplantation are currently investigated in two on-going Phase II
studies in sensitized kidney patients in Sweden and the US. The Swedish study
will be completed in Q4 2016 and the U.S. study is estimated to be completed
during H1 2017. In addition to transplantation, IdeS has potential applications
in a variety of rare autoimmune diseases.
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory
enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Additional projects focus on development of new antibody modulating enzymes, as
well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency
departments that is already introduced on the market. The company is based in
Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq
Last updated on: 03/10/2016